A phase 1 study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours

被引：0
|
作者：
Cresti, N. [1 ]
Jodrell, D. [2 ]
Arkenau, T. [3 ]
Forster, M. [4 ]
Donaldson, K. [5 ]
Posner, J. [5 ]
Kawabata, I. [5 ]
Plummer, R. [1 ]
Spicer, J. [6 ]
机构：
[1] Northern Ctr Canc Care, Newcastle Upon Tyne, Tyne & Wear, England
[2] Univ Cambridge, Dept Oncol, Cambridge, England
[3] Sarah Cannon Res UK, London, England
[4] Univ Coll Hosp, London, England
[5] Shionogi & Co Ltd, Osaka, Japan
[6] Kings Coll London, Guys Hosp, London WC2R 2LS, England
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
800
引用
收藏
页码：S160 / S161
页数：2
相关论文
共 50 条
  • [1] Phase 1 dose-escalation study of S-222611, an oral reversible dual tyrosine kinase inhibitor of EGFR and HER2, in patients with solid tumours
    Spicer, J.
    Baird, R.
    Suder, A.
    Cresti, N.
    Corbacho, J. Garcia
    Hogarth, L.
    Frenkel, E.
    Matsumoto, S.
    Kawabata, I.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 (02) : 137 - 145
  • [2] A phase I study of S-222611 an oral reversible dual inhibitor of EGFR and HER2, in patients with solid tumors
    Baird, Richard D.
    Papa, Sophie
    Cresti, Nicola
    Hatcher, Helen
    Hogarth, Linda
    Jamal-Hanjani, Mariam
    Frenkel, Eugene P.
    Donaldson, Kirsteen
    Posner, John
    Kawabata, Izumi
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including patients with brain metastases.
    Deva, Sanjeev
    Baird, Richard D.
    Cresti, Nicola
    Garcia-Corbacho, Javier
    Hogarth, Linda
    Frenkel, Eugene P.
    Kawaguchi, Keiko
    Arimura, Akinori
    Donaldson, Kirsteen
    Posner, John
    Sarker, Debashis
    Jodrell, Duncan Ian
    Plummer, Ruth
    Spicer, James F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours
    Arkenau, H. -T.
    Italiano, A.
    Mak, G.
    Toulmonde, M.
    Baird, R. D.
    Garcia-Corbacho, J.
    Plummer, R.
    Flynn, M.
    Forster, M.
    Wilson, R. H.
    Tosi, D.
    Adenis, A.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Arimura, A.
    Deva, S.
    Spicer, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2018, 103 : 17 - 23
  • [5] Phase I expansion of S-222611, a reversible inhibitor of EGFR and HER2, in advanced solid tumors, including HER2-positive breast cancer patients with brain metastases
    Baird, R. D.
    Arkenau, H-T
    Deva, S.
    Cresti, N.
    Garcia-Corbacho, J.
    Hogarth, L.
    Frenkel, E.
    Kawaguchi, K.
    Arimura, A.
    Donaldson, K.
    Posner, J.
    Sarker, D.
    Jodrell, D.
    Plummer, R.
    Spicer, J.
    Italiano, A.
    [J]. CANCER RESEARCH, 2016, 76
  • [6] Phase I trial of S-222611, a dual tyrosine kinase inhibitor of EGFR and HER2, with preliminary evidence of efficacy in patients (pts) with heavily-pretreated HER2-positive metastatic breast cancer
    Baird, R. D.
    Cresti, N.
    Beddowes, E.
    Saggese, M.
    Flynn, M.
    Corbacho, J. Garcia
    Gao, F.
    Lemech, C.
    Donaldson, K.
    Posner, J.
    Kawabata, I.
    Forster, M.
    Arkenau, H. T.
    Plummer, R.
    Jodrell, D.
    Spicer, J.
    [J]. CANCER RESEARCH, 2013, 73
  • [7] A phase I/II of S-222611, a reversible EGFR and HER2 inhibitor, combined with trastuzumab plus /- chemotherapy in patients with HER2-positive metastatic breast cancer
    Rafii, S.
    Macpherson, I.
    Baird, R.
    Saggese, M.
    Spiliopoulou, P.
    Kumar, S.
    Italiano, A.
    Bonneterre, J.
    Campone, M.
    Cresti, N.
    Posner, J.
    Takeda, Y.
    Arimura, A.
    Spicer, J.
    [J]. CANCER RESEARCH, 2017, 77
  • [8] S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: in vitro kinase inhibition and antitumor activity
    Hirata, Michinari
    Tanaka, Hidekazu
    Dohi, Keiji
    Iguchi, Motofumi
    Wada, Tohru
    Matsuo, Kenji
    Kume, Masaharu
    Omori, Naoki
    Tada, Yukio
    Orita, Satoshi
    Abe, Kenji
    Arimura, Akinori
    Matsuo, Yoshiyuki
    Kato, Akira
    [J]. CANCER RESEARCH, 2009, 69
  • [9] S-222611, a potent, orally active small molecule inhibitor of EGFR and HER2: In vivo antitumor effects
    Iguchi, Motofumi
    Tanaka, Hidekazu
    Wada, Tohru
    Hojo, Kanji
    Shinonome, Satomi
    Sato, Norihito
    Nezasa, Ken-ichi
    Orita, Satoshi
    Abe, Kenji
    Arimura, Akinori
    Matsuo, Yoshiyuki
    Kato, Akira
    [J]. CANCER RESEARCH, 2009, 69
  • [10] Antitumor activities of EGFR/HER2/HER4 kinase inhibitor S-222611 in the experimental brain metastases of HER2-positive breast cancer
    Hirata, Michinari
    Tanaka, Yukari
    Shinonome, Satomi
    Yamada, Tomomi
    Torii, Mikinori
    Nezasa, Kenichi
    Tanaka, Hidekazu
    [J]. CANCER RESEARCH, 2017, 77
12345